biOasis, AstraZeneca deal

biOasis partnered with AstraZeneca's MedImmune LLC biologics unit to evaluate MedImmune's preclinical compounds with next-generation versions of biOasis' Transcend brain delivery technology. Transcend is a soluble p97 (melanotransferrin) carrier protein that transports therapeutics across the blood-brain barrier (BBB) using receptor-mediated transcytosis. The partners did not disclose financial terms. ...